Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 5311-5315

  Whitehurst, Christopher B ^a   Sanders, Marcia K ^b   Law, Mankit ^a   Wang, Fu Zhang ^a   Xiong, Jie ^c   Dittmer, Dirk P ^a,b   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; MESSENGER RNA; UNCLASSIFIED DRUG; VIRAL PROTEIN KINASE BGLF4; VIRUS ENZYME;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EPSTEIN BARR VIRUS; GENE DOSAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSCRIPTION; VIRUS ATTENUATION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS TRANSCRIPTION; VIRUS TRANSCRIPTION INHIBITION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL LINE; DOWN-REGULATION; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOSIDES; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; MUSHROOM BACILLIFORM VIRUS;

EID: 84876307966     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03505-12     Document Type: Article

References (30)

1. Biron KK. 2006. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71:154-163.
2. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340:1462-1470.
3. ViroPharma Incorporated. 2012. ViroPharma announces initiation of clinical studies to evaluate maribavir for treatment of cytomegalovirus (CMV) infection. ViroPharma Incorporated, Exton, PA.
4. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M. 2008. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, doseranging study. Blood 111:5403-5410.
5. Price NB, Prichard MN. 2011. Progress in the development of new therapies for herpesvirus infections. Curr. Opin. Virol. 1:548-554.
6. Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER. 2003. In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.
7. Zacny VL, Gershburg E, Davis MG, Biron KK, Pagano JS. 1999. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-Lribofuranosyl-1H-benzimidazole. J. Virol. 73:7271-7277.
8. Gershburg E, Hong K, Pagano JS. 2004. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob. Agents Chemother. 48:1900-1903.
9. Ljungman P. 2002. Prevention and treatment of viral infections in stem cell transplant recipients. Br. J. Haematol. 118:44-57.
10. Pagano JS. 1995. Epstein-Barr virus: therapy of active and latent infection, p 155-195. In Jeffries DJ, De Clercq E (ed), Antiviral chemotherapy. John Wiley & Sons Ltd., Hoboken, NJ.
11. Pagano JS, Sixbey JW, Lin JC. 1983. Acyclovir and Epstein-Barr virus infection. J. Antimicrob. Chemother. 12(Suppl. B):113-121.
12. Slifkin M, Doron S, Snydman DR. 2004. Viral prophylaxis in organ transplant patients. Drugs 64:2763-2792.
13. Bogner E. 2002. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:115-127.
14. Dittmer A, Drach JC, Townsend LB, Fischer A, Bogner E. 2005. Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J. Virol. 79:14660-14667.
15. Evers DL, Komazin G, Ptak RG, Shin D, Emmer BT, Townsend LB, Drach JC. 2004. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 48:3918-3927.
16. Kern ER, Hartline CB, Rybak RJ, Drach JC, Townsend LB, Biron KK, Bidanset DJ. 2004. Activities of benzimidazole D-and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother. 48:1749-1755.
17. Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Westerman AC, Biron KK, Townsend LB, Drach JC. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
18. Prichard MN. 2009. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 19:215-229.
19. Prichard MN, Frederick SL, Daily S, Borysko KZ, Townsend LB, Drach JC, Kern ER. 2011. Benzimidazole analogs inhibit human herpesvirus 6. Antimicrob. Agents Chemother. 55:2442-2445.
20. Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
21. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith IA, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW. 2002. Potent and selective inhibition of human cytomegalovirus Replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
22. Biron KK. 2011. Maribavir: a novel bensimidole ribonucleoside for the prevention and treatment of cytomegalovirus disease antiviral drug strategies. In Erik De Clercq (ed), Antiviral drug strategies, 1st ed. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi:10.1002/9783527635955.ch9.
23. Gershburg E, Pagano JS. 2005. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother. 56:277-281.
24. Gershburg E, Pagano JS. 2002. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J. Virol. 76:998-1003.
25. Wang FZ, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS. 2009. Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. J. Virol. 83:12108-12117.
26. Murata T, Isomura H, Yamashita Y, Toyama S, Sato Y, Nakayama S, Kudoh A, Iwahori S, Kanda T, Tsurumi T. 2009. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Virology 389:75-81.
27. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
28. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440-9445.
29. Gershburg E, Raffa S, Torrisi MR, Pagano JS. 2007. Epstein-Barr virusencoded protein kinase (BGLF4) is involved in production of infectious virus. J. Virol. 81:5407-5412.
30. Zhu J, Liao G, Shan L, Zhang J, Chen MR, Hayward GS, Hayward SD, Desai P, Zhu H. 2009. Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4. J. Virol. 83:5219-5231.